Octreotide LAR for the treatment of acromegaly

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):783-93. doi: 10.1517/17425255.4.6.783.


Background: Somatostatin analogs previously considered as adjuvant therapy in acromegaly are increasingly used as a first-line therapy in selected cases.

Objective: To review the octreotide LAR pharmacological and clinical data, and discuss the impact of this agent on current treatment regimens.

Methods: We reviewed PubMed publications since the first use of octreotide LAR in acromegaly, and historical articles related to the discovery and development of this molecule. We chose, for efficacy and safety data, reviews, clinical and randomized controlled trials that included >or=10 patients.

Results/conclusion: Octreotide LAR controls acromegaly in approximately 50-60% of patients by inhibiting GH and IGF-I secretion, and by reducing tumor size. This drug is well tolerated in most patients.

Publication types

  • Review

MeSH terms

  • Acromegaly / drug therapy*
  • Acromegaly / etiology
  • Acromegaly / metabolism
  • Adenoma / complications
  • Adenoma / drug therapy*
  • Adenoma / metabolism
  • Animals
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / pharmacokinetics
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Chemistry, Pharmaceutical
  • Delayed-Action Preparations
  • Growth Hormone-Secreting Pituitary Adenoma / complications
  • Growth Hormone-Secreting Pituitary Adenoma / drug therapy*
  • Growth Hormone-Secreting Pituitary Adenoma / metabolism
  • Human Growth Hormone / antagonists & inhibitors*
  • Human Growth Hormone / metabolism
  • Humans
  • Octreotide / adverse effects
  • Octreotide / pharmacokinetics
  • Octreotide / therapeutic use*
  • Treatment Outcome


  • Antineoplastic Agents, Hormonal
  • Delayed-Action Preparations
  • Human Growth Hormone
  • Octreotide